Enter any phrase or word you would like to search for and click .
PostNews: Press Release
Notice that Interim Report 3 2022/23 will be published already on March 28, 2023
PHI changes the date for publication of Interim Report 3 2022/23 to March 28, 2023.
Learn more …
PostNews: Press Release

PHI creates a subsidiary for the anticipated EU patent concerning synthetic antibodies
PHI has decided to create a dedicated subsidiary to house the synthetic antibody patent family and facilitate its business potential.
Learn more …
PostBlog Post

CERN seminar: The Promise of Regenerative Medicine and AI
During this seminar, Peter Egelberg, Founder of PHI, will present the work carried out by PHI in the development of time-lapse cytometry instrumentation and software.
Learn more …
PostNews

BioStock: PHI catches eye of major investor
BioStock contacted Altium’s CEO Goran Dubravcic to learn more about their incentives to invest in PHI.
Learn more …
PostNews: Press Release
Swiss-based Altium acquires major stake in PHI
PHI announces that Altium S.A. recently acquired Formue Nord’s entire holdings in PHI of 2 416 679 shares and 1 491 362 TO 3 warrants and committed to exercise the obtained warrants.
Learn more …
PostNews

BioStock: PHI comments on the new senior positions in the company
BioStock reached out to Patrik Eschricht and Peter Egelberg to better understand the background behind the recent management shift.
Learn more …